porozendoОстеопороз и остеопатииOsteoporosis and Bone Diseases2072-26802311-0716Endocrinology Research Centre10.14341/osteo2010342-49porozendo-4196Research ArticleСтатьиArticlesПРИВЕРЖЕННОСТЬ К ЛЕЧЕНИЮ ОСТЕОПОРОЗА: ВОПРОСПЕРЕНОСИМОСТИ, РЕЖИМА ЛЕЧЕНИЯИЛИ ИСКЛЮЧИТЕЛЬНО ХОРОШЕГО ДИАЛОГА С ПАЦИЕНТОМ?PRIVERZhENNOST' K LEChENIYu OSTEOPOROZA: VOPROSPERENOSIMOSTI, REZhIMA LEChENIYaILI ISKLYuChITEL'NO KhOROShEGO DIALOGA S PATsIENTOM?FANGEn S.-SPEKTORTim D.-FUNGEn. C.-SPECTORTim D.-201015122010133№3 (2010)4249Copyright © FANG E.S., SPEKTOR T.D., FUNG E.C., SPECTOR T.D., 20102010FANG E.S., SPEKTOR T.D., FUNG E.C., SPECTOR T.D.FANG E.S., SPEKTOR T.D., FUNG E.C., SPECTOR T.D.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.osteo-endojournals.ru/jour/article/view/4196

Good antifracture treatment efficacy requires adherence, which is often suboptimal. The most common reason for nonadherence is real or perceived intolerance to the medication. Although dosage frequency plays a significant role, pharmacokinetics is but one of many barriers to adherence. Patient-related factors are an important consideration, but a good doctor-patient relationship with clear communication can enable patients to make more-informed choices when deciding their treatment. It is possible to improve adherence, but a multimodal approach is needed to achieve this aim.

ReferencesEFFO and NOF Consensus Development Statement. Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int. 1997;7:1-6.EFFO and NOF Consensus Development Statement. Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int. 1997;7:1-6.Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726-1733.Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726-1733.Sambrook P. Compliance with treatment in osteoporosis patients-an ongoing problem. Aust Fam Physician. 2006;35:135-137.Sambrook P. Compliance with treatment in osteoporosis patients-an ongoing problem. Aust Fam Physician. 2006;35:135-137.NICE. Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk. 2008. http://www.nice. org.uk/nice media/pdf/OsteoporosisEvidenceReviews190908.pdfNICE. Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk. 2008. http://www.nice. org.uk/nice media/pdf/OsteoporosisEvidenceReviews190908.pdfKanis JA, Oden A, Johansson H, Borgström F, Ström O, McCloskey E. FRAX and its applications to clinical practice. Bone. 2009:44:734-743.Kanis JA, Oden A, Johansson H, Borgström F, Ström O, McCloskey E. FRAX and its applications to clinical practice. Bone. 2009:44:734-743.Kothawala R, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82:1493-1501.Kothawala R, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82:1493-1501.Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int. 2007;18:711-719.Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int. 2007;18:711-719.Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21:1453-1460.Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21:1453-1460.Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19:48 811-818.Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19:48 811-818.Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38:922-928.Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38:922-928.Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81: 1013-1022.Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81: 1013-1022.Gallagher AM, Rietbrock S, Olson M, van Staa TP. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res. 2008;23:1569-1575.Gallagher AM, Rietbrock S, Olson M, van Staa TP. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res. 2008;23:1569-1575.Sebaldt RJ, Shane LG, Pham B, Cook R, Thabane L, Petrie A. Long term effectiveness outcomes of non-compliance and non-persistence with daily regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care. Osteoporos Int. 2004;15:S107.Sebaldt RJ, Shane LG, Pham B, Cook R, Thabane L, Petrie A. Long term effectiveness outcomes of non-compliance and non-persistence with daily regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care. Osteoporos Int. 2004;15:S107.Toteston AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;15:209-216.Toteston AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;15:209-216.Lau E, Papaioannou A, Dolovich L, et al. Patients' adherence to osteoporosis therapy. Exploring the perceptions of postmenopausal women. Can Fam Physician. 2008;54:394-402.Lau E, Papaioannou A, Dolovich L, et al. Patients' adherence to osteoporosis therapy. Exploring the perceptions of postmenopausal women. Can Fam Physician. 2008;54:394-402.Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate. The Fracture Interventional Trial. Arch Intern Med. 2000;160: 517-525.Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate. The Fracture Interventional Trial. Arch Intern Med. 2000;160: 517-525.Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc. 2002;77:1031-1043.Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc. 2002;77:1031-1043.Greenspan S, Field-Munves E, Tonino R, et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebocontrolled study. Mayo Clin Proc. 2002;77:1044-1052.Greenspan S, Field-Munves E, Tonino R, et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebocontrolled study. Mayo Clin Proc. 2002;77:1044-1052.Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Safety. 2007;30:755-763.Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Safety. 2007;30:755-763.Recker RR, Lewiecki M, Miller PD, Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med. 2009;122:S22-S32.Recker RR, Lewiecki M, Miller PD, Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med. 2009;122:S22-S32.Stevenson M, Lloyd-Jones M, Nigris ED, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess. 2005;9(22).Stevenson M, Lloyd-Jones M, Nigris ED, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess. 2005;9(22).Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 2003;14:259-262.Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 2003;14:259-262.Miller PD, Woodson G, Licata AA, et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther. 2000;22:1433-1442.Miller PD, Woodson G, Licata AA, et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther. 2000;22:1433-1442.Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab. 1999;84:3076-3081.Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab. 1999;84:3076-3081.Joint Formulary Committee. British National Formulary. 57th ed. London, UK: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2009.Joint Formulary Committee. British National Formulary. 57th ed. London, UK: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2009.Reid IR. Osteonecrosis of the jaw-who gets it, and why? Bone. 2009;44: 4-10.Reid IR. Osteonecrosis of the jaw-who gets it, and why? Bone. 2009;44: 4-10.Silverman SL, Landersberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med. 2009;122:S33-S45.Silverman SL, Landersberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med. 2009;122:S33-S45.Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008;42:841-847.Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008;42:841-847.Black DM, Delmas PD, Eastell R; for the HORIZON Pivotal Fracture Trial Group. Once-yearly zoledronic acid 5mg for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.Black DM, Delmas PD, Eastell R; for the HORIZON Pivotal Fracture Trial Group. Once-yearly zoledronic acid 5mg for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.Felsenberg D, Hoffmeister B, Amling M, et al. Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Dtsch Arztebl. 2006;103:3078-3081.Felsenberg D, Hoffmeister B, Amling M, et al. Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Dtsch Arztebl. 2006;103:3078-3081.Mavrokokki A, Cheng A, Stein B, Goss AN. The nature and frequency of bisphosphonateassociated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65:415-423.Mavrokokki A, Cheng A, Stein B, Goss AN. The nature and frequency of bisphosphonateassociated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65:415-423.Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459-468.Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459-468.Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: TROPOS study. J Clin Endocrinol Metab. 2005;90:2816-2822.Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: TROPOS study. J Clin Endocrinol Metab. 2005;90:2816-2822.Stevenson M, Davis S, Lloyd-Jones M, Beverley C. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol Assess. 2007;11(4).Stevenson M, Davis S, Lloyd-Jones M, Beverley C. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol Assess. 2007;11(4).O'Donnell S, Cranney A, Wells GA, Adachi J, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis (Review). Cochrane Database of Systematic Reviews. 2006;issue 4.O'Donnell S, Cranney A, Wells GA, Adachi J, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis (Review). Cochrane Database of Systematic Reviews. 2006;issue 4.Pernicova I, Middleton ET, Aye M. Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert. Osteoporos Int. 2008;19:1811-1812. Letter.Pernicova I, Middleton ET, Aye M. Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert. Osteoporos Int. 2008;19:1811-1812. Letter.European Public Assessment Reports (EPARs) for authorised medicinal products for human use. Protelos. 2007. Press Release. Available at http://www. emea.europa.eu/humandocs/PDFs/EPAR/protelos/ PressRelease_Protelos_ 41745807en.pdfEuropean Public Assessment Reports (EPARs) for authorised medicinal products for human use. Protelos. 2007. Press Release. Available at http://www. emea.europa.eu/humandocs/PDFs/EPAR/protelos/ PressRelease_Protelos_ 41745807en.pdfEttinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in ostmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-645.Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in ostmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-645.Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321- 333.Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321- 333.Col NF, Bowlby LA, McGarry K. The role of menopausal hormone therapy in preventing osteoporotic fractures: a critical review of the clinical evidence. Minnerva Med. 2005;96:331-342.Col NF, Bowlby LA, McGarry K. The role of menopausal hormone therapy in preventing osteoporotic fractures: a critical review of the clinical evidence. Minnerva Med. 2005;96:331-342.Compston J. How to manage osteoporosis after the menopause. Best Pract Res Clin Rheumatol. 2005;19:1007-1019.Compston J. How to manage osteoporosis after the menopause. Best Pract Res Clin Rheumatol. 2005;19:1007-1019.Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359:697-708.Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359:697-708.Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ. Patient preference for once-weekly alendronate 70mg versus once-daily alendronate 10mg: a multicenter, randomized, open-label, crossover study. Clin Ther. 2002;24:1871-1886.Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ. Patient preference for once-weekly alendronate 70mg versus once-daily alendronate 10mg: a multicenter, randomized, open-label, crossover study. Clin Ther. 2002;24:1871-1886.Kendler D, Kung AW, Fuleihan Gel-H, et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas. 2004;48:243-251.Kendler D, Kung AW, Fuleihan Gel-H, et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas. 2004;48:243-251.Richards JB, Cherkas LF, Spector TD. An analysis of which anti-osteoporosis therapeutic regimen would improve compliance in a population of elderly adults. Curr Med Res Opin. 2007;23:293-299.Richards JB, Cherkas LF, Spector TD. An analysis of which anti-osteoporosis therapeutic regimen would improve compliance in a population of elderly adults. Curr Med Res Opin. 2007;23:293-299.Weiss TW, McHorney CA. Osteoporosis medication profile preference: results from the PREFER-US study. Health Expectations. 2007;10:211-223.Weiss TW, McHorney CA. Osteoporosis medication profile preference: results from the PREFER-US study. Health Expectations. 2007;10:211-223.Fraenkel L, Gulanski B, Wittink D. Patient treatment preferences for osteoporosis. Arthritis Rheum. 2006;55:729-735.Fraenkel L, Gulanski B, Wittink D. Patient treatment preferences for osteoporosis. Arthritis Rheum. 2006;55:729-735.Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. IMAJ. 2003;5:859-862.Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. IMAJ. 2003;5:859-862.Jamal SA, Ridout R, Chase C, Fielding L, Rubin LA, Hawker GA. Bone mineral density testing and osteoporosis education improve lifestyle behaviors in premenopausal women: a prospective study. J Bone Miner Res. 1999;14: 2143-2149.Jamal SA, Ridout R, Chase C, Fielding L, Rubin LA, Hawker GA. Bone mineral density testing and osteoporosis education improve lifestyle behaviors in premenopausal women: a prospective study. J Bone Miner Res. 1999;14: 2143-2149.Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165:2414-2419.Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165:2414-2419.Bergmann P, Body JJ, Boonen S, et al; Members of Advisory Board on Bone Markers. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of biphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract. 2009;63:19-26.Bergmann P, Body JJ, Boonen S, et al; Members of Advisory Board on Bone Markers. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of biphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract. 2009;63:19-26.Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353: 487-497.Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353: 487-497.Harrington JT, Barash HL, Day S, Lease J. Redesigning the care of fragility fracture patients to improve osteoporosis management: a health care improvement project. Arthr Rheum. 2005;53:198-204.Harrington JT, Barash HL, Day S, Lease J. Redesigning the care of fragility fracture patients to improve osteoporosis management: a health care improvement project. Arthr Rheum. 2005;53:198-204.Clowes JA, Peel NFA, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:1117-1123.Clowes JA, Peel NFA, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:1117-1123.

The authors declare that there are no conflicts of interest present.